Pathology

Jian Huang, MD

Assistant Professor of Pathology
Director of Tissue Procurement and Quality Control

Dr. Huang is a trained research pathologist with over 20 years experience in cancer research. Dr. Huang had been participating in many large breast cancer related  research projects during last 6 years. These research projects included Breast SPORE, PPG, Susan G. Komen, RO1 grants. Currently, Dr. Huang oversees the process of tissue procurement and tissue quality control for the MCW tissue bank, and also provides pathology related services/consults to all MCW faculty for their research projects.

Research Interests

• To determine the roles of ER-a36 in HER2 signaling in breast cancer
• To understand the molecular mechanisms of how tetraspanin family regulates the trafficking of estrogen receptor(s) in breast cancer
• To develop novel biomarkers in breast cancer

Professional Background

• Associate Professor, Vice-Chair, Department of Pathology, Guangdong Medical College, The P. R. of China (12/1998 - 3/2001)
• Assistant Professor of Pathology, Director of the Pathology Core Laboratory, The Lester and Sue Smith Breast Center, Baylor College of Medicine (10/2005-10/2010)
• Assistant Professor of Pathology, Department of Pathology; Director of Tissue Procurement and Quality Control, MCW Tissue Bank (11/2010 – Present)

Educational Background

• Gannan Medical College (Clinical Medicine), MD
• Tongji  Medical University (Pathology, Tumor Biology), MPH
• Kansas State University (Tumor Biology), Postdoctoral Fellowship
• University of California at San Francisco (Molecular and Cellular Biology), Postdoctoral Fellowship

Selected Publications

• Huang J, et al.  Estrogen Receptor-alpha 36 crosstalks with HER2 signaling in breast cancer.  Manuscript.
• Jiang L and Huang J.  Tetraspanin LAMP3/CD63 regulates non-classical ERα signaling pathway in breast cancer. Submitted.
• Qi XM, Zhi HY, Lepp A,Wang P, Huang J, Basir Z, Chitambar CR, Myers CR and Chen G. P38&[gamma] MAPK confers breast cancer hormone sensitivity by switching estrogen receptor (ER) signaling from the classical to the non-classical pathway via stimulating ER phosphorylation and c-Jun transcription. JBC 2012, March 7. In Press.
•  Sun T, Aceto N, Meerbrey KL, Kessler JD, Zhou C, Migliaccio I, Nguyen DX, Pavlova NN, Botero M, Huang J, Bernardi RJ, Schmitt E, Hu G, Li MZ, Dephoure N, Gygi SP, Rao M, Creighton CJ, Hilsenbeck SG, Shaw CA, Muzny D, Gibbs RA, Wheeler DA, Osborne CK, Schiff R, Bentires-Alj M, Elledge SJ, Westbrook TF. Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase. Cell  2011, 144(5):703-18.
• Qu Y, Wang J, Ray PS, Guo H, Huang J, Shin-Sim M, Bukoye BA, Liu B, Lee AV, Lin X, Huang P, Martens JW, Giuliano AE, Zhang N, Cheng NH, Cui X. Thioredoxin-like 2 regulates human cancer cell growth and metastasis via redox homeostasis and NF-κB signaling. J Clin Invest. 2011;121(1):212–225.
• Bu W, Chen J, Morrison1 GD, Huang S, Creighton CJ, Huang J, Chamness GC, Hilsenbeck SG, Roop DR, Leavitt AD, and Li Y.   Keratin 6a marks mammary bipotential progenitor cells that can give rise to a unique tumor model resembling human normal-like breast cancer. Oncogene 2011, May 2.
• Liu R, Zhou ZM, Huang J, Chen CS. PEMPA1 promotes prostate cell proliferation through suppressing the Smad3/4-c-Myc-p21Cip1 signaling pathway. J PATHOL  2011, 223(5):683-94.
• Cheng CM, Li H, Gasman S, Huang J, Schiff R, Chang EC. Compartmentalized Ras proteins transform NIH3T3 cells with different efficiencies. Mol Cell Biol. 2011,31(5):983-97.
• Dave B, Migliaccio I, Gutierrez MC, Wu MF, Chamness GC, Wong H, Narasanna A, Chakrabarty A, Hilsenbeck SG, Huang J, Rimawi M, Schiff R, Arteaga C, Osborne CK, Chang JC.     Loss of Phosphatase and Tensin Homolog or hosphoinositol-3 Kinase Activation and Response to Trastuzumab or Lapatinib in Human Epidermal Growth Factor Receptor 2-Overexpressing Locally Advanced Breast Cancers.   J Clin Oncol. 2011, 29(2):166-73.
• Massarweh S, Tham YL, Huang J, Sexton K,Weiss H, Tsimelzon A,Bayer A, Rimawi M, Cai WY, Hilsenbeck S, Fuqua S, and Elledge R. A phase II neoadjuvant trial of anastrozole, fulvestrant and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer. Breast Cancer Research and Treatment 2011, 129(3):819-27.
• Toneff MJ, Du Z, Dong J, Huang J, Sinai P, Forman J, Hilsenbeck S, Schiff R, Huang S, Li Y. Somatic expression of PyMT or activated ErbB2 induces estrogen-independent mammary tumorigenesis.  Neoplasia. 2010 Sep;12(9):718-26.
• Jiang L, Huang J. Crosstalk between estrogen receptor alpha 36, a dominant extra-nuclear ER, and HER2 promotes tumor cell survival in breast cancer. Cancer Research 2009; 69(24): 632s (Supplement).
• Zheng HQ, Zhou ZM, Huang J, Chaudhury L, Dong JT, Chen CS. Krüppel-Like Factor 5 Promotes Breast Cell Proliferation Partially through Upregulating the Transcription of Fibroblast Growth Factor-Binding Protein. Oncogene 2009; 28(42):3702-13.
• Li X, Lewis MT, Huang J,  Gutierrez C, Osborne CK, Wu MF, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC, Wong H, Rosen J, Chang JC.  Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008; 100(9):672-9.
• Huang J, Allred DC. The distribution of luminal, basal, and stem cell biomarkers in normal human breast tissue. Breast Cancer Research and Treatment 2006; Vol. 100, Supplement: S167.